OAC vs. LFMD, AUNA, NGNE, TBPH, ANNX, ZJYL, PEPG, EDIT, SLRN, and ESPR
Should you be buying Oaktree Acquisition stock or one of its competitors? The main competitors of Oaktree Acquisition include LifeMD (LFMD), Auna (AUNA), Neurogene (NGNE), Theravance Biopharma (TBPH), Annexon (ANNX), Jin Medical International (ZJYL), PepGen (PEPG), Editas Medicine (EDIT), Acelyrin (SLRN), and Esperion Therapeutics (ESPR). These companies are all part of the "medical" sector.
Oaktree Acquisition (NYSE:OAC) and LifeMD (NASDAQ:LFMD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, community ranking, analyst recommendations and risk.
LifeMD received 24 more outperform votes than Oaktree Acquisition when rated by MarketBeat users. However, 100.00% of users gave Oaktree Acquisition an outperform vote while only 71.05% of users gave LifeMD an outperform vote.
In the previous week, LifeMD had 4 more articles in the media than Oaktree Acquisition. MarketBeat recorded 5 mentions for LifeMD and 1 mentions for Oaktree Acquisition. LifeMD's average media sentiment score of 0.50 beat Oaktree Acquisition's score of 0.00 indicating that LifeMD is being referred to more favorably in the news media.
47.6% of Oaktree Acquisition shares are held by institutional investors. Comparatively, 35.5% of LifeMD shares are held by institutional investors. 18.9% of LifeMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Oaktree Acquisition has higher earnings, but lower revenue than LifeMD.
Oaktree Acquisition has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, LifeMD has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
LifeMD has a consensus price target of $12.60, indicating a potential upside of 60.71%. Given LifeMD's higher possible upside, analysts plainly believe LifeMD is more favorable than Oaktree Acquisition.
Oaktree Acquisition has a net margin of 0.00% compared to LifeMD's net margin of -14.75%.
Summary
LifeMD beats Oaktree Acquisition on 8 of the 13 factors compared between the two stocks.
Get Oaktree Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for OAC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oaktree Acquisition Competitors List
Related Companies and Tools
